Brief: Bellerophon Therapeutics Announces FDA Clears Initiation Of Phase 3 Study For Inopulse® Inhaled Nitric Oxide Therapy To Treat Covid-19
11/05/2020 13:41
May 11 (Reuters) - Bellerophon Therapeutics Inc BLPH.O :
* BELLEROPHON THERAPEUTICS ANNOUNCES FDA CLEARS INITIATION
OF
PHASE 3 STUDY FOR INOPULSE® INHALED NITRIC OXIDE THERAPY TO
TREAT COVID-19
* BELLEROPHON - FDA ACCEPTED IND APPLICATION, ALLOWING CO TO
INITIATE PHASE 3 STUDY OF INOPULSE INO THERAPY IN UP TO 500
PATIENTS INFECTED WITH COVID-19
Source text for Eikon: ID:nGNX5nzjKV
Further company coverage: BLPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bellerophon Therapeutics
See all newsBrief: Bellerophon Therapeutics Inc On October 12, 2023, Board Of Directors Approved Plan Of Liquidation And Dissolution Of Company
Bellerophon Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Bellerophon Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Archer-Daniels-Midland, Nucor, Copper miners
U.S. STOCKS ON THE MOVE-Hubbell, Spire Global, FibroGen